# US 2022/0033436 A1 · Derivative of sarsasapogenin, pharmaceutical composition and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033436 A1
- Document ID: US20220033436A1
- Status: Published application
- Kind: A1
- Application number: 17/279,732
- Filed: 2019-05-13
- Published: 2022-02-03
- Earliest claimed: 2018-09-29
- Assignees: Phytovent Biopharma
- Applicants: Phytovent Biopharma
- Inventors: Shawn Mu; Na Wang
- Web page: https://patentgrep.com/patent/US20220033436A1

## CPC

- A61P 25/00: Drugs for disorders of the nervous system
- C07J 71/0005: {Oxygen-containing hetero ring}
- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07J: STEROIDS (seco-steroids C07C)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A derivative of sarsasapogenin is provided having a structure of formula I, A pharmaceutical composition of the aforementioned derivative of sarsasapogenin and use thereof are also provided. By systematic modification and derivatization of sarsasapogenin structure in combination with inhibitory activity assays on tumor cells, many derivative compounds are provided that have excellent inhibitory activity on tumor cells, particularly high inhibitory activity on the growth of various brain tumor cells, having potential wide application and tremendous value in treating various cancers.

## Claims

### Claim 1

A derivative of sarsasapogenin having a structure of formula I,
wherein, Z is selected from a monoheterocyclyl, a diheterocyclyl, and NR1R2, the monoheterocyclyl or diheterocyclyl containing one or two heteroatoms selected from sulfur, oxygen, NH and NRa; R1 and R2 are each independently selected from hydrogen and substituted or unsubstituted C1-C10 alkyl, or together form a 3-8 membered ring containing one or more substituents selected from C1-C10 alkyl, C3-C10 cycloalkyl, C6-C20 aryl, C3-C14 heteroaryl, halogen, hydroxyl, amino, nitro, cyano, formyl, carboxyl, alkoxy, —CF3, —SF5 and 3-8 membered heterocyclyl containing one or more heteroatoms selected from sulfur, oxygen, NH and NRa;
X is selected from C(Rb)(Rc), C(O), and S(O)2, Rb and Rc together form a 3-8 membered carbocyclyl or a 3-8 membered heterocyclyl containing one or more heteroatoms selected from sulfur, oxygen, N, NH and NRa, the 3-8 membered carbocyclyl or the 3-8 membered heterocyclyl being optionally substituted with one or more substituents selected from C1-C10 alkyl, C3-C10 cycloalkyl, C6-C20 aryl, C3-C14 heteroaryl, halogen, hydroxyl, amino, nitro, cyano, formyl, carboxyl, alkoxy, —CF3, —SF5 and 3-8 membered heterocyclyl containing one or two heteroatoms selected from O, S and NRa;
Y is selected from C(Rd)(Re), C(O), and S(O)2, and Rd and Re together form a 3-8 membered ring or a 3-8 membered heterocyclyl containing one or two heteroatoms selected from sulfur, oxygen, NH and NRa;
Ra, Rb, Rc, Rd and Re are independently selected from C1-C10 alkyl, C3-C10 cycloalkyl, C6-C20 aryl and C3-C14 heteroaryl optionally substituted with at least one substituent selected from halogen, hydroxyl, amino, nitro, cyano, formyl, carboxyl, alkoxy, —CF3, and —SF5;
X is C(Rb)(Rc), Y is C(Rd)(Re), and Rb and Rd are connected through a chemical bond;
n is an integer selected from 0 to 10; and
m is selected from 0 and 1.

### Claim 2 (depends on 1)

The derivative of sarsasapogenin according to claim 1, wherein the structure of the derivative is shown by formula II,

### Claim 3 (depends on 1)

The derivative of sarsasapogenin according to claim 1, wherein the structure of the derivative is shown by formula III,

### Claim 4 (depends on 1)

The derivative of sarsasapogenin according to claim 1, wherein the structure of the derivative is shown by formula IV,

### Claim 5 (depends on 1)

The derivative of sarsasapogenin according to claim 1, wherein the derivative is selected from one of the following compounds, a mixture of diastereomers of the following compounds and an enantiomer of the following compounds,

### Claim 6 (depends on 1)

The derivative of sarsasapogenin according to claim 1, wherein one or more hydrogen atoms of the derivative are deuterium atoms.

### Claim 7 (depends on 1)

A pharmaceutical composition, comprising a first ingredient or a combination of the first ingredient and a second ingredient, wherein
the first ingredient is the derivative of sarsasapogenin according to claim 1, a pharmaceutically acceptable salt, stereoisomer, tautomer or prodrug thereof, or a pharmaceutically acceptable carrier thereof; and
the second ingredient is an anti-tumor agent selected from one or more of a chemotherapeutic agent, a targeted agent against tumor and an anti-tumor antibody.

### Claim 8 (depends on 7)

The pharmaceutical composition according to claim 7, wherein the pharmaceutically acceptable salt is selected from one or more of hydrochloride, hydrobromide, sulfate, phosphate, mesylate, benzenesulfonate, p-toluenesulfonate, 1-naphthalene sulfonate, 2-naphthalene sulfonate, acetate, trifluoroacetate, malate, tartrate, citrate, lactate, oxalate, succinate, fumarate, maleate, benzoate, salicylate, phenylacetate and mandelate; and the anti-tumor agent is selected from one or more of PD-1 antibody, CTLA-4 antibody, PD-L1 antibody and PD-L2 antibody.

### Claim 9 (depends on 7)

Use of the pharmaceutical composition according to claim 7 in preparing a medicament for treating cancers, eye diseases, psychological disorders, depression, anxiety, Alzheimer's disease, and/or autoimmune diseases.

### Claim 10 (depends on 9)

The use of the pharmaceutical composition according to claim 9, wherein the cancers include colon cancer, breast cancer, gastric cancer, lung cancer, colorectal cancer, pancreatic cancer, ovarian cancer, prostatic cancer, kidney cancer, liver cancer, brain cancer, melanoma, multiple myeloma, chronic myelocytic leukemia, hematological neoplasm, lymphoid tumor, or other metastatic lesions in tissues or organs remote from primary tumor sites.

### Claim 11 (depends on 2)

The derivative of sarsasapogenin according to claim 2, wherein the structure of the derivative is shown by formula IV,
